Navigation Links
Myeloproliferative in Medical News

Late-breaking data to be presented at the American Society of Hematology Annual Meeting

... of a new tumor suppressor gene in patients with myeloproliferative disorders. "There is now additional evidence ... is a Novel Tumor Suppressor Gene Inactivated in myeloproliferative Neoplasms: Identification of a Pre-JAK2 V617F ... which is altered in 14 percent of patients with myeloproliferative disorders, providing scientists with a greater ...

Cytopia Lodges IND for JAK2 Inhibitor CYT387

... is implicated in a variety of haematological conditions known as the myeloproliferative disorders (MPDs). This suite of conditions includes myelofibrosis, ... with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders and cancer, expected to enter Phase I clinical studies in 2009. ...

Scientists Identify Key Gene That Protects Against Leukemia

... led by 6 to 12 months post-transplantation to the development of a myeloproliferative disease, which can evolve to leukemia. The finding indicated that the ... lineage than the control group, indicating constant regeneration of a myeloproliferative disease from JunB-deficient HSCs that persisted after treatment. When ...

S*BIO Announces Collaboration with Onyx for JAK2 Inhibitors in the North American and European Markets

... of SB1518 will initially focus on the treatment of myelofibrosis and other myeloproliferative diseases. JAK2 inhibitors are implicated across a broad range of ... V617F mutation. The V617F mutation is found in high frequencies in various myeloproliferative disorders such as idiopathic myelofibrosis. SB1518 might also provide an ...

Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO

... activation of JAK2 stimulates blood cell production. Genetic mutations in the JAK2 enzyme result in up-regulated activity and are implicated in myeloproliferative diseases (MPD), conditions characterized by an overproduction of blood cells in the bone marrow. The MPD conditions where JAK2 mutations are most ...

Experimental Drug Fights Bone Marrow Cancers

... TUESDAY, Dec. 9 (HealthDay News) -- An experimental drug called CYT387 blocks an enzyme that causes bone marrow cancers called myeloproliferative disorders (MPDs), according to U.S. researchers who conducted tests in mice and human cells. The findings were to be presented Tuesday at the ...

Dr. Richard M. Soll Joined WuXi PharmaTech (NYSE: WX) as VP of Medicinal Chemistry

... nomination candidates and clinical development drugs for potential treatment for cancer, thrombosis, ocular disease, inflammation, edema and myeloproliferative disorders. As the Vice President of Medicinal Chemistry Dr. Soll will help the company to expand and strengthen its medicinal chemistry services ...

Increased cancer risk following the use of radioactive Radium-224 in the therapy

... "It is rather unlikely that impurities present in the radium preparations used before 1950 are responsible for the elevated appearance of myeloproliferative diseases in the exposed group observed here," commented Dr. Roland R. Wick. "In addition, the increased incidence of leukaemia is in line with ...

Singapore Is One of the Fastest Growing Bioclusters in Asia; Wave of Investments in Drug Discovery and Translational Research

... class cancer therapy. In addition, S*Bio received orphan drug approval from FDA to conduct clinical trials for a drug that is designed to treat myeloproliferative disorders (MPD), a disease which if untreated can lead to cardiovascular diseases and leukemia. 3. The Institute of Bioengineering and ...

Stem cell research leads to potential new therapy for rare blood disorder

... A unique partnership between industry and academia has led to human clinical trials of a new drug for a rare class of blood diseases called myeloproliferative disorders (MPD), which are all driven by the same genetic mutation and can evolve into leukemia. In just one year, collaborative discoveries by stem ...
Myeloproliferative in Medical Technology

Late-Breaking Data Highlighting Research Advances in Several Blood Disorders to Be Presented At the American Society of Hematology Annual Meeting

... of a new tumor suppressor gene in patients with myeloproliferative disorders. "There is now additional ... Novel Tumor Suppressor Gene Inact i vated in myeloproliferative Neoplasms: Identification of a Pre- J AK2 ... which is altered in 14 percent of patients with myeloproliferative disorders, providing scientists with a greater ...

Cytopia Scientific Presentations on JAK2 Inhibitor Program

... a lecture entitled Targeted JAK2 Inhibitors for myeloproliferative Disorders at the annual meeting of the ... will present his lecture JAK2 Inhibitors for myeloproliferative Disorders at the 'Drug Discovery on Target' ... as a potent and selective compound for treating myeloproliferative disorders (MPDs). Subject to regulatory ...

Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders

... for formal preclinical development to treat myeloproliferative disorders (MPDs). This follows extensive ... an in-vivo model of myeloproliferative disease. myeloproliferative disorders are a group of diseases ... efficacy in a well-validated in-vivo model of myeloproliferative disorders in studies in the laboratory ...

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

... lestaurtinib inhibits FLT3 activity and induces cell death (apoptosis). In myeloproliferative disorders, mutations in JAK2 may play a role in allowing large numbers of ... this activity, lestaurtinib is in ongoing studies for the treatment of myeloproliferative disorders. About Cephalon Oncology Cephalon, a leading ...

TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients

... results from a multi-center, US-based clinical trial of TG101348 in myeloproliferative disease patients has been scheduled at the 2008 American Society of ... Dr. Animesh Pardanani, Mayo Clinic Session Name: myeloproliferative Disorders-Experimental Therapeutics Session Date: Sunday, ...

TargeGen Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients

... an oral, potent, and highly selective inhibitor of JAK2 in patients with myeloproliferative diseases. (Logo: ... (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce ...

TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH

... A JAK2 Selective Small Molecule Inhibitor, in the Presence of myeloproliferative Disorder-Associated JAK2V617F, MPLW515K, or Exon 12 Mutations -- ... (ET) and primary myelofibrosis (PMF). In preclinical models of myeloproliferative diseases, TG101348, administered orally, was shown to reduce to reduce ...

Mutant Genes in High-Risk Childhood Leukemias Identified

... clinical trials of inhibitory drugs to treat such cancers. "JAK-inhibiting drugs are now moving into clinical trials for treatment of such adult myeloproliferative diseases as polycthemia vera, essential thrombocytosis and primary myelofibrosis," Downing said. "We expect that there will soon be initial clinical ...

Ipsogen Expands its US Market Presence Through Licensing Agreement With ARUP Laboratories for the Commercialization of JAK2 Molecular Diagnostic Assays

... development, non-exclusive rights, for the US territory, to offer a complete range of assays for the molecular classification and the screening of myeloproliferative Neoplasms (MPN), a group of leukaemia's caused by JAK2 gene variations that affects more than 100,000 people in the US. Additional terms were not ...

Cytopia Concludes Phase I Oral Trial for Vascular-Disrupting Agent, CYT997

... to build on its range of JAK inhibitors and kinase expertise. CYT387, a novel, orally administered JAK2 inhibitor focused on the treatment of myeloproliferative disorders is expected to enter Phase I clinical studies in 2009. ...
Myeloproliferative in Medical Definition

Hematopathology

... . Diseases of Hematopoietic Cells The major disease of hematopoietic cells fall into several categories, which include chronic myeloproliferative disease , myelodysplastic syndromes , leukemias , lymphomas , plasma cell neoplasms , and histiocytic and mast cell neoplasms. ...
Myeloproliferative in Medical Dictionary

Myeloproliferative Disorders

... myeloproliferative disorders : Malignant disease s of certain bone ... platelet s (crucial to blood clotting). myeloproliferative disorders are a group of disease s in which the ... or platelet s. There are 6 types of chronic myeloproliferative disorders . Expanded indication: treatment ...

Polycythemia

... caused by sickle cell disease , may cause blood clots to form. The myeloproliferative disorders include myelophthisic anemia , erythroblastic leukemia , ... indication: treatment of patients with thrombocythemia, secondary to myeloproliferative disorders such as polycythemia vera (PV) and chronic myelogenous ...

Polycythemia vera

... chronic , progressive disease , most common in middle-aged men. The myeloproliferative disorders include myelophthisic anemia , erythroblastic leukemia , ... indication: treatment of patients with thrombocythemia, secondary to myeloproliferative disorders such as polycythemia vera (PV) and chronic myelogenous ...

Osler

... me about hereditary hemorrhagic telangiectasia ? Diane/ Canada ... : Cryptogenic Polycythemia , Erythremia, Erythrocytosis Megalosplenica, myeloproliferative Disorder, Osler 's Disease , Polycythemia Rubra Vera, Polycythemia with Chronic Cyanosis - Myelopathic Polycythemia , Primary ...

Platelet count

... bleeding . Adult treatment usually begins with oral prednisone. Expanded indication: treatment of patients with thrombocythemia, secondary to myeloproliferative disorders such as polycythemia vera (PV) and chronic myelogenous leukemia ( CML ), to reduce the elevated platelet count and the risk of ...
Myeloproliferative in Biological News

La Jolla Institute discovers novel tumor suppressor

... as a tumor suppressor that may be important in myeloproliferative diseases and some types of lymphoma and leukemia. myeloproliferative diseases are a group of disorders characterized ... further, choosing to focus specifically on myeloproliferative disease because almost all of the mice with a ...

Scientists identify key gene that protects against leukemia

... led by 6 to 12 months post-transplantation to the development of a myeloproliferative disease, which can evolve to leukemia. The finding indicated that the ... lineage than the control group, indicating constant regeneration of a myeloproliferative disease from JunB-deficient HSCs that persisted after treatment. When ...

Genetic abnormality may increase risk of blood disorders

... inherited DNA sequence changes that frequently occur in patients with myeloproliferative neoplasms, in which several types of blood cells are excessively produced ... by the DNA sequence. More than half of patients afflicted with myeloproliferative neoplasms which affect an estimated 140,000 people in the US carry the ...

AACR hosts Molecular Diagnostics in Cancer Therapeutic Development Meeting

... Genetic markers for glioblastoma survival New data on nanotechnology as a cost effective diagnostic method More accurate tools for diagnosing myeloproliferative neoplasia Late-breaking data on multispectral imaging and its utility How the Epstein Barr virus predicts outcome in nasopharyngeal carcinoma ...
Myeloproliferative in Biological Technology

Cytopia Letter to Progen Shareholders

... with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009. ... with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009. ...

Presentation on Cytopia's JAK2 Inhibitor Program in Myeloproliferative Disorders

... University and will overview the study of CYT387 in an in- vivo model of myeloproliferative disorders. Full presentation details: Effects of ... with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in early 2009. ...

Three Astex Drug Candidates to be Presented at the 2007 American Society of Hematology Annual Meeting

... 3127 Title: AT9283, a Potent Inhibitor of JAK2, Is Active in JAK2 V617F myeloproliferative Disease Models. Session Name: myeloproliferative Syndromes: Therapy Session Date: Monday, December 10, 2007 Presentation ...

Oral VDA CYT997 - Phase I Clinical Trial Presentation at ASCO

... is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in mid 2009. Website: www.cytopia.com.au ...

Cytopia Presentation on VDA CYT997 at AACR Conference

... is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009. Website: www.cytopia.com.au ...

Cytopia Scientific Presentation on JAK2 Inhibitor Program at American Chemical Society Conference

... to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009. Website: www.cytopia.com.au ...

Progen Concedes Shareholder Requisitioned Meeting

... is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in 2009. ...

Cytopia and Other Progen Shareholders Maintain Call for Meeting

... to build on its range of JAK inhibitors and kinase expertise. CYT387, a novel, orally administered JAK2 inhibitor focused on the treatment of myeloproliferative disorders is expected to enter Phase I clinical studies in 2009. ...

Progen Shareholders Call Meeting to Spill Progen Board and Offer Merger or Full Cash Back to Shareholders

... is continuing to build on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase I clinical studies in early 2009. Website: www.cytopia.com.au Director Candidate Biographies Mr. ...

In 2008, Ipsogen Reinforced its Leadership in Molecular Diagnosis and Monitoring of Leukemia

... a significant role in the monitoring of this disease. - MutaScreen MPL, a research kit for the detection of MPL mutations in JAK2 negative myeloproliferative neoplams (MPN), is a significant addition to the MPD family of products that Ipsogen offers. These 3 new tests exemplify Ipsogen's ...
Myeloproliferative in Biological Dictionary

Nucleolar organizer

... Organizer ' How to ... nucleolar organizer . Type: Term. Definitions: ... Nucleolar organizer regions of megakaryocytes in chronic myeloproliferative disorders. ... Alteration of argyrophilic nucleolar organizer region associated (Ag ... In recent years, nucleolar organizer region (NOR) ...

Basophils

... UFP ... What is Basophils ? Meaning of Basophils medical term. What does Basophils mean? ... The relative number of basophils increases in myeloproliferative diseases and ... 1.3.1 Mast cells and basophils ... Basophils are the smallest circulating granulocytes with relatively the least known ...
Other Contents
(Date:9/4/2015)... ... September 04, 2015 , ... Bio-Logic Aqua® Research, a fresh ... its only mission and research focus: Water Life Science®. In the current warming ... evaporation is becoming dangerously accelerated. As a result of the global fresh water, ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... ... on: the microbiome taking place in Hollywood, Florida October 9-10, 2015 at the ... Speakers at the 2015 symposium are doctors and researchers at the top of ...
(Date:9/4/2015)... ... September 04, 2015 , ... ECC announces the site ... specifically for adults with intellectual, developmental and acquired disabilities. The first community, named ... cottage or “pocket” homes. In this community, adults will live safely and permanently ...
(Date:9/4/2015)... ... 2015 , ... Steven Winter Associates, Inc., (SWA) is pleased ... for the Residential Award of Merit by the Connecticut Green Building Council (CTGBC) ... highly competitive field of submissions, the net-zero energy residence will be honored at ...
(Date:9/4/2015)... ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... prophetic details involving the Pope’s upcoming trip to the United States. , Yisrayl lays out ... role with the Vatican and society is. Yisrayl also provides the meaning of his own ...
Breaking Medicine News(10 mins):Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 2Health News:Bio-Logic Aqua® Research Announces Water Life Science and Body Water Evaporation as Research Focus and Mission 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 2Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 3Health News:Cottage Home Communities for Disabled Adults to Create First Viable Permanent Housing Option 4Health News:South Glastonbury Home Selected for Award by Connecticut Green Building Council 2Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2
(Date:8/11/2015)... Today, ZUK announced its Android smartphone Z1, ... expected revenues in 2015 that relate to sales of FPC1155 for ... approximately 2,200 MSEK for 2015. Jörgen Lantto, CEO of ... smartphone manufacturer in China and ... 155 for Z1 , ...
(Date:8/6/2015)... BOSTON and TELTOW, Germany ... the 2015 Siggraph Conference, SensoMotoric Instruments (SMI) ... augmented reality , based on Epson,s Moverio ... eye tracking platform. With this new solution, unprecedented quality ... multi-modal, hands-free interaction with context-sensitive displays. For the first ...
(Date:8/5/2015)... 2015 The biosensors market is proving highly ... into newer sectors, and development of devices resulting in ... has seen the entry of multiple participants each year ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... the Global Biosensors Market ( http://www.frost.com/nee9 ), finds ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1155 in ZUK's Smartphone Z1 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4
Other TagsOther Tags